(23S,24S)-1-beta-[O-(4-O-acetyl-alpha-L-rhamnopyranosyl)-(1→2)-O-[beta-D-xylopyranosyl-(1→3)]-alpha-L-arabinopyranosyl) oxy]-3-beta-23-dihydroxyspirosta-5,25(27)-dien-24-yl-beta-D-fucopyranoside - Compound Card

(23S,24S)-1-beta-[O-(4-O-acetyl-alpha-L-rhamnopyranosyl)-(1→2)-O-[beta-D-xylopyranosyl-(1→3)]-alpha-L-arabinopyranosyl) oxy]-3-beta-23-dihydroxyspirosta-5,25(27)-dien-24-yl-beta-D-fucopyranoside

Select a section from the left sidebar

(23S,24S)-1-beta-[O-(4-O-acetyl-alpha-L-rhamnopyranosyl)-(1→2)-O-[beta-D-xylopyranosyl-(1→3)]-alpha-L-arabinopyranosyl) oxy]-3-beta-23-dihydroxyspirosta-5,25(27)-dien-24-yl-beta-D-fucopyranoside

Structure
Zoomed Structure
  • Family: Plantae - Dracaenaceae
  • Kingdom: Plantae
  • Class: Steroid
    • Subclass: Saponin
Canonical Smiles CC(=O)O[C@H]1C(C)O[C@H](C([C@H]1O)O)O[C@@H]1[C@@H](OC[C@@H](C1O[C@@H]1OC[C@H](C([C@@H]1O)O)O)O)O[C@@H]1C[C@H](O)CC2=CC[C@@H]3[C@@H]([C@@]12C)CC[C@]1([C@H]3C[C@H]2[C@@H]1[C@H](C)[C@@]1(O2)OCC(=C)C(C1O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O)O)O)C
InChI InChI=1S/C51H78O23/c1-18-15-66-51(44(63)40(18)71-46-38(61)35(58)33(56)20(3)67-46)19(2)32-30(74-51)14-27-25-9-8-23-12-24(53)13-31(50(23,7)26(25)10-11-49(27,32)6)70-48-43(73-47-39(62)36(59)41(21(4)68-47)69-22(5)52)42(29(55)17-65-48)72-45-37(60)34(57)28(54)16-64-45/h8,19-21,24-48,53-63H,1,9-17H2,2-7H3/t19-,20+,21?,24+,25+,26-,27-,28+,29-,30-,31+,32-,33-,34?,35-,36+,37-,38+,39?,40?,41-,42?,43-,44?,45-,46-,47-,48-,49-,50-,51-/m0/s1
InChIKey PPBMRFNEMIFFFJ-WKXUWDKPSA-N
Formula C51H78O23
HBA 23
HBD 11
MW 1059.16
Rotatable Bonds 9
TPSA 341.13
LogP -2.25
Number Rings 10
Number Aromatic Rings 0
Heavy Atom Count 74
Formal Charge 0
Fraction CSP3 0.9
Exact Mass 1058.49
Number of Lipinski Rule Violations 3
# Species Family Kingdom NCBI Taxonomy ID
1 Sansevieria trifasciata Dracaenaceae Plantae 39534

Showing of synonyms

  • Teponno RB, Tanaka C, et al. (2016). Trifasciatosides A-J, Steroidal Saponins from Sansevieria trifasciata.. Chemical & pharmaceutical bulletin,2016, 64(9), 1347-1355. [View] [PubMed]

No compound-protein relationship available.

Structure

SMILES: O1CCCCC1OC(C(=C)CO2)CC23CC4C5C(CC4O3)C6C(CC5)C7C(=CC6)CCCC7OC8OCCC(OC9CCCCO9)C8OC1CCCCO1

Level: 4

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CCCCC1OC(C(=C)CO2)CC23CC4C5C(CC4O3)C6C(CC5)C7C(=CC6)CCCC7OC(OCCC8)C8OC9CCCCO9

Level: 3

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CCCCC1OC(C(=C)CO2)CC23CC4C5C(CC4O3)C6C(CC5)C7C(=CC6)CCCC7OC(OCC8)CC8OC9CCCCO9

Level: 3

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CC(=C)CCC12CC3C4C(CC3O2)C5C(CC4)C6C(=CC5)CCCC6OC7OCCC(OC8CCCCO8)C7OC9CCCCO9

Level: 3

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CCCCC1OC(C(=C)CO2)CC23CC4C5C(CC4O3)C6C(CC5)C7C(=CC6)CCCC7OC8CCCCO8

Level: 2

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CC(=C)CCC12CC3C4C(CC3O2)C5C(CC4)C6C(=CC5)CCCC6OC(OCCC7)C7OC8CCCCO8

Level: 2

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CC(=C)CCC12CC3C4C(CC3O2)C5C(CC4)C6C(=CC5)CCCC6OC(OCC7)CC7OC8CCCCO8

Level: 2

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CCCCC1OC2C(COCC2)OC3CCCCO3

Level: 2

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CCCCC1OC(C(=C)CO2)CC23CC4C5C(CC4O3)C6C(CC5)C7C(=CC6)CCCC7

Level: 1

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CC(=C)CCC12CC3C4C(CC3O2)C5C(CC4)C6C(=CC5)CCCC6OC7CCCCO7

Level: 1

Mol. Weight: 1059.16 g/mol

Structure

SMILES: C1OCCCC1OC2CCCCO2

Level: 1

Mol. Weight: 1059.16 g/mol

Structure

SMILES: C1COCCC1OC2CCCCO2

Level: 1

Mol. Weight: 1059.16 g/mol

Structure

SMILES: O1CC(=C)CCC12CC3C4C(CC3O2)C5C(CC4)C6C(=CC5)CCCC6

Level: 0

Mol. Weight: 1059.16 g/mol

Structure

SMILES: C1CCOCC1

Level: 0

Mol. Weight: 1059.16 g/mol

No bioactivities available.

Absorption

Caco-2 (logPapp)
-6.41
Human Oral Bioavailability 20%
Non-Bioavailable
Human Intestinal Absorption
Non-Absorbed
Madin-Darby Canine Kidney
304250.6
Human Oral Bioavailability 50%
Non-Bioavailable
P-Glycoprotein Inhibitor
Non-Inhibitor
P-Glycoprotein Substrate
Non-Substrate
Skin Permeability
39762816.05

Distribution

Blood-Brain Barrier (CNS)
-
Blood-Brain Barrier
Non-Penetrable
Fraction Unbound (Human)
0.68
Plasma Protein Binding
70.49
Steady State Volume of Distribution
-

Metabolism

Breast Cancer Resistance Protein
Non-Inhibitor
CYP 1A2 Inhibitor
Non-Inhibitor
CYP 1A2 Substrate
Non-Substrate
CYP 2C19 Inhibitor
Non-Inhibitor
CYP 2C19 Substrate
Non-Substrate
CYP 2C9 Inhibitor
Non-Inhibitor
CYP 2C9 Substrate
Non-Substrate
CYP 2D6 Inhibitor
Non-Inhibitor
CYP 2D6 Substrate
Non-Substrate
CYP 3A4 Inhibitor
Non-Inhibitor
CYP 3A4 Substrate
Substrate
OATP1B1
Non-Inhibitor
OATP1B3
Non-Inhibitor

Excretion

Clearance
2.01
Organic Cation Transporter 2
Non-Inhibitor
Half-Life of Drug
-

Toxicity

AMES Mutagenesis
Safe
Avian
Toxic
Bee
Safe
Bioconcentration Factor
-924787.21
Biodegradation
Safe
Carcinogenesis
Safe
Crustacean
Toxic
Liver Injury I (DILI)
Toxic
Eye Corrosion
Safe
Eye Irritation
Safe
Maximum Tolerated Dose
-1.68
Liver Injury II
Safe
hERG Blockers
Toxic
Daphnia Maga
4.05
Micronucleos
Toxic
NR-AhR
Safe
NR-AR
Safe
NR-AR-LBD
Safe
NR-Aromatase
Safe
NR-ER
Safe
NR-ER-LBD
Safe
NR-GR
Safe
NR-PPAR-gamma
Safe
NR-TR
Safe
T. Pyriformis
-72167584959.83
Rat (Acute)
4.11
Rat (Chronic Oral)
155.41
Fathead Minnow
91096246.49
Respiratory Disease
Toxic
Skin Sensitisation
Safe
SR-ARE
Safe
SR-ATAD5
Safe
SR-HSE
Safe
SR-MMP
Toxic
SR-p53
Safe

General Properties

Boiling Point
8116848066.43
Hydration Free Energy
-2.92
Log(D) at pH=7.4
-4499.71
Log(P)
-0.2
Log S
-2.58
Log(Vapor Pressure)
-267283526.28
Melting Point
262.18
pKa Acid
-1947489.75
pKa Basic
-15654.87

No predicted protein targets found for this compound.

Download SDF